Johnson & Johnson (FRA:JNJ)
177.00
-2.90 (-1.61%)
At close: Dec 19, 2025
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 29, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
€570,643
Profits / Employee
€155,552
Market Cap
424.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Deutsche Post AG | 573,964 |
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
Johnson & Johnson News
- 3 days ago - FDA Approves J&J's New 5-Minute Injection For Lung Cancer - Benzinga
- 3 days ago - J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant - Nasdaq
- 3 days ago - Noteworthy ETF Inflows: IWX, JNJ, BAC, WFC - Nasdaq
- 3 days ago - Johnson & Johnson (JNJ) Receives FDA Approval for Expanded Use of TRUFILL System - GuruFocus
- 3 days ago - Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma - PRNewsWire
- 3 days ago - FDA Approves Injectable Rybrevant for JNJ, Offering New NSCLC Treatment Option - GuruFocus
- 3 days ago - J&J wins FDA nod for Rybrevant injectable in lung cancer - Seeking Alpha
- 4 days ago - Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization - Seeking Alpha